Summary of Significant Accounting Policies - Additional Information (Details) (USD $)
|
3 Months Ended |
|
Mar. 31, 2015
Segment
Entity
|
Mar. 31, 2014
|
Dec. 31, 2014
Entity
|
Organization And Significant Accounting Policies [Line Items] |
|
|
|
Research and development commitments with third parties not incurred |
$ 6,828,000xon_ResearchAndDevelopmentCommitmentsNotYetIncurred |
|
$ 2,183,000xon_ResearchAndDevelopmentCommitmentsNotYetIncurred |
Maturity period of liquid investment |
3 months |
|
|
Cash equivalent investments in highly liquid money market accounts |
87,768,000us-gaap_MoneyMarketFundsAtCarryingValue |
|
16,598,000us-gaap_MoneyMarketFundsAtCarryingValue |
Number of collaborators over which the Company has significant influence |
2xon_NumberOfCollaborators |
|
2xon_NumberOfCollaborators |
Fair value of financial assets measured at fair value on a recurring basis |
387,188,000us-gaap_AssetsFairValueDisclosure |
|
280,497,000us-gaap_AssetsFairValueDisclosure |
Unrealized appreciation (depreciation) in the fair value of the Company's equity securities |
115,454,000us-gaap_FairValueOptionChangesInFairValueGainLoss1 |
21,922,000us-gaap_FairValueOptionChangesInFairValueGainLoss1 |
|
Variable interest entities, risk of loss |
192,228,000us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount |
|
0us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount |
Percentage of recognized income tax positions |
50.00%xon_IncomeTaxBenefitRecognitionCriteriaPercentageThreshold |
|
|
Number of segment |
1us-gaap_NumberOfOperatingSegments |
|
|
Revenues |
33,849,000us-gaap_Revenues |
7,854,000us-gaap_Revenues |
|
Foreign Countries |
|
|
|
Organization And Significant Accounting Policies [Line Items] |
|
|
|
Long-lived assets |
82,133,000us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = xon_ForeignCountriesMember |
|
17,100,000us-gaap_NoncurrentAssets / us-gaap_StatementGeographicalAxis = xon_ForeignCountriesMember |
Revenues |
1,290,000us-gaap_Revenues / us-gaap_StatementGeographicalAxis = xon_ForeignCountriesMember |
0us-gaap_Revenues / us-gaap_StatementGeographicalAxis = xon_ForeignCountriesMember |
|
Equity Securities |
|
|
|
Organization And Significant Accounting Policies [Line Items] |
|
|
|
Fair value of financial assets measured at fair value on a recurring basis |
294,922,000us-gaap_AssetsFairValueDisclosure / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember |
|
164,889,000us-gaap_AssetsFairValueDisclosure / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember |
Oragenics, Inc. |
|
|
|
Organization And Significant Accounting Policies [Line Items] |
|
|
|
Company's ownership percentage |
22.40%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_OragenicsMember |
|
24.40%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_OragenicsMember |
Oragenics, Inc. | Equity Securities |
|
|
|
Organization And Significant Accounting Policies [Line Items] |
|
|
|
Fair value of financial assets measured at fair value on a recurring basis |
8,128,000us-gaap_AssetsFairValueDisclosure / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_OragenicsMember |
|
7,192,000us-gaap_AssetsFairValueDisclosure / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_OragenicsMember |
Unrealized appreciation (depreciation) in the fair value of the Company's equity securities |
936,000us-gaap_FairValueOptionChangesInFairValueGainLoss1 / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_OragenicsMember |
710,000us-gaap_FairValueOptionChangesInFairValueGainLoss1 / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_OragenicsMember |
|
ZIOPHARM Oncology, Inc. |
|
|
|
Organization And Significant Accounting Policies [Line Items] |
|
|
|
Company's ownership percentage |
13.90%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_ZiopharmMember |
|
15.70%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_ZiopharmMember |
ZIOPHARM Oncology, Inc. | Equity Securities |
|
|
|
Organization And Significant Accounting Policies [Line Items] |
|
|
|
Fair value of financial assets measured at fair value on a recurring basis |
192,032,000us-gaap_AssetsFairValueDisclosure / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_ZiopharmMember |
|
83,099,000us-gaap_AssetsFairValueDisclosure / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_ZiopharmMember |
Unrealized appreciation (depreciation) in the fair value of the Company's equity securities |
$ 96,334,000us-gaap_FairValueOptionChangesInFairValueGainLoss1 / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_ZiopharmMember |
$ 3,934,000us-gaap_FairValueOptionChangesInFairValueGainLoss1 / us-gaap_FairValueByAssetClassAxis = us-gaap_EquitySecuritiesMember / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = xon_ZiopharmMember |
|
Minimum |
|
|
|
Organization And Significant Accounting Policies [Line Items] |
|
|
|
Weighted Average Useful Life (Years) |
2 years |
|
|
Minimum | Leasehold Improvements |
|
|
|
Organization And Significant Accounting Policies [Line Items] |
|
|
|
Property plant and equipment, useful life |
1 year |
|
|
Maximum |
|
|
|
Organization And Significant Accounting Policies [Line Items] |
|
|
|
Weighted Average Useful Life (Years) |
14 years |
|
|
Maximum | Leasehold Improvements |
|
|
|
Organization And Significant Accounting Policies [Line Items] |
|
|
|
Property plant and equipment, useful life |
14 years |
|
|